Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze EGRX stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate EGRX investment potential.

What is EGRX stock price today?

Get real-time EGRX stock price, historical data, and price charts on Financhill. Track EGRX performance with our advanced analysis tools.

Is EGRX a good investment?

Evaluate EGRX investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy EGRX stock?

To buy EGRX stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of EGRX?

View detailed market capitalization data and company valuation metrics for EGRX on our comprehensive analysis page.

What is the P/E ratio of EGRX?

Use our fundamental analysis tools to view EGRX P/E ratio and compare valuation metrics with industry peers.

What are EGRX earnings?

View EGRX earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Eagle Pharmaceuticals, Inc. 10K Form

Sell

EGRX
Eagle Pharmaceuticals, Inc.

Last Price:

$0.25

Seasonality Move:

-10.89%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-08-09	10Q	EGRX/Eagle Pharmaceuticals, Inc. Quarterly
2023-08-08	10Q	EGRX/Eagle Pharmaceuticals, Inc. Quarterly
2023-05-09	10Q	EGRX/Eagle Pharmaceuticals, Inc. Quarterly
2022-11-09	10Q	EGRX/Eagle Pharmaceuticals, Inc. Quarterly
2022-08-09	10Q	EGRX/Eagle Pharmaceuticals, Inc. Quarterly
2022-05-09	10Q	EGRX/Eagle Pharmaceuticals, Inc. Quarterly

Receive EGRX News And Ratings

See the #1 stock for the next 7 days that we like better than EGRX

EGRX Financial Statistics

Sales & Book Value

Annual Sales:	$316.6M
Cash Flow:	$0
Price / Cash Flow:	0
Annual Sales:	$0.00
Price / Book:	0.01

Profitability

Net Income (TTM):	$0
Gross Margin:	$221M
Return on Equity:	0%
Return on Assets:	0%

Eagle Pharmaceuticals, Inc. Earnings Forecast

Key Eagle Pharmaceuticals, Inc. Financial Ratios

The Gross Profit Margin over the past 11 years for EGRX is 69.81%.
The Selling, General & Administrative Expenses for EGRX have been equal to 33.68% of Gross Profit Margin.
The Research & Development expenses have been 10.71% of Revenue.
The Interest Expense is 11.35% of Operating Income.
The Net Earning history of EGRX is 11.26% of Total Revenues.
Per Share Earnings over the last 11 years have been positive in 4 years.

Eagle Pharmaceuticals, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	OTCM
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	EGRX
CUSIP:	269796
Website:	eagleus.com

Debt

Debt-to-Equity Ratio:	0
Current Ratio:	0
Quick Ratio:	0

Price-to-Earnings

Trailing P/E Ratio:	0.09
Forward P/E Ratio:	0

EGRX Technical Analysis vs Fundamental Analysis